Giovanni Caforio, Bristol Myers Squibb CEO

More deals ahead for Bris­tol My­ers? CEO Gio­van­ni Caforio touts 'size ag­nos­tic' BD strat­e­gy

De­spite gener­ics eat­ing away at one of Bris­tol My­ers Squibb’s high­est sell­ers last year, Revlim­id, CEO Gio­van­ni Caforio main­tained on Wednes­day’s Q2 call that the com­pa­ny’s “foun­da­tion is strong” — and that he has all the tools nec­es­sary to keep build­ing, in­clud­ing a fast-pro­gress­ing late-stage pipeline and an eye for deals of all sizes.

The phar­ma gi­ant has a lot rid­ing on two as­sets in par­tic­u­lar: its Phase III-ready an­tithrom­bot­ic mil­vex­i­an, and deu­cravac­i­tinib, which is due for an FDA de­ci­sion in Sep­tem­ber in mod­er­ate to se­vere pso­ri­a­sis. In the mean­time, Caforio said he is on the hunt for more deals like the com­pa­ny’s re­cent $4.1 bil­lion takeover of Turn­ing Point, which is ex­pect­ed to close this quar­ter.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.